Associated Papers
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Tan L et al.
Nature Communications, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid.
Sheng Z et al.
Frontiers in Oncology, 2023
Enhancing oral squamous cell carcinoma prediction: the prognostic power of the worst pattern of invasion and the limited impact of molecular resection margins.
Hurník P et al.
Frontiers in Oncology, 2023
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T et al.
Nature Communications, 2022
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Gounder MM et al.
Nature Communications, 2022
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
Leskela S et al.
The American Journal of Surgical Pathology, 2020
Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis.
He CY et al.
Clinical and Translational Medicine, 2020
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
The long tail of oncogenic drivers in prostate cancer.
Armenia J et al.
Nature Genetics, 2018
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L et al.
Nature Communications, 2018
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
Berenjeno IM et al.
Nature Communications, 2017
Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma.
Wrzeszczynski KO et al.
Neurology. Genetics, 2017
Neomorphic mutations create therapeutic challenges in cancer.
Takiar V et al.
Oncogene, 2017
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
Giudice FS et al.
Journal of Carcinogenesis & Mutagenesis, 2013
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Ross RL et al.
Plos One, 2013
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Santarpia L et al.
Breast Cancer Research and Treatment, 2012
Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking.
Mellor P et al.
The Biochemical Journal, 2012
Structural effects of oncogenic PI3Kα mutations.
Gabelli SB et al.
Current Topics in Microbiology and Immunology, 2010
PI3K regulatory subunits lose control in cancer.
Berenjeno IM et al.
Cancer Cell, 2009
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Unknown Author
Nature, 2008